Merck Serono Takes Action Against Illegal Online Drug Sales
This article was originally published in PharmAsia News
Executive SummaryMerck Serono China, subsidiary of Germany-based Merck, recently issued a statement revealing that some Chinese websites have been illegally selling drugs using the firm's brand names without its knowledge or permission. None of the drugs sold are developed, produced and marketed by Merck Serono, nor have they obtained the company's sales authorization. The websites and drugs include Moxue-Xianfuan by www.merckdx.com, Moxue-Mianfuan by www.merck-china.net and www.merckchina99.com, and Moxue-Meiluoxin by www.mxmnw.com. Merck Serono China has reported the illicit operations to relevant authorities and demanded severe punishments, with the rights to take further legal actions. (Click here for more - Chinese language)
You may also be interested in...
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.